Report Highlights

UK Propolis Market: Market Overview

The UK propolis market was valued at £187.4 million in 2024, driven by sustained consumer demand for natural immune support, antimicrobial alternatives, and clean-label cosmetic ingredients. The market structure is fragmented, with domestic beekeeping operations supplying only a minority of raw material requirements and a significant share of finished product volume originating from New Zealand Māori-certified sources and Brazilian green propolis exporters. Government policy has not historically been the dominant market-shaping force in this category; consumer health trends and retailer listings at Boots, Holland & Barrett, and Amazon UK have exercised greater commercial influence than any single regulatory instrument.

However, the post-Brexit regulatory reconfiguration is rapidly repositioning government as a market architect. The Food Standards Agency's retained authority over Novel Foods, the MHRA's jurisdiction over medicinal claims on botanical products, and the Competition and Markets Authority's 2023 enforcement focus on greenwashing in health product marketing are collectively creating a compliance architecture that is fundamentally reshaping product formulation, labelling strategy, and market entry economics. Companies that treated propolis as a loosely regulated food supplement before 2021 are now navigating a distinctly more demanding environment in which specific claims require specific authorisations.

Policy-Driven Growth in the UK Propolis Market

Three policy mechanisms are actively driving demand growth in UK propolis. First, the UK Nutrition and Health Claims Register, maintained under retained Regulation (EC) No 1924/2006 and administered by the Food Standards Agency, creates a defined pathway for propolis products to carry substantiated immunity and antioxidant claims. Companies successfully navigating this register gain a significant competitive advantage in pharmacy-channel listings, where evidence-backed claims are a prerequisite for shelf placement. This mechanism converts regulatory compliance investment directly into market access and commands price premiums of 20–35% over unclaimed commodity products.

Second, the Defra Healthy Bees Plan 2030, a funded government programme allocating resources to apiary disease management and hive productivity, indirectly expands the domestic raw material base by supporting colony health across England and Wales. Third, the NHS antimicrobial resistance strategy, operationalised through the UK AMR National Action Plan 2019–2024 and its successor framework, is generating institutional research funding for propolis-derived compounds at institutions including Cardiff University, which creates downstream commercial licensing opportunities and supports claims substantiation dossiers used in FSA Novel Food applications. Each mechanism has a distinct and traceable pathway to market volume expansion.

Regulatory Barriers and Compliance Costs

The primary regulatory barrier is the Novel Food authorisation process administered by the Food Standards Agency under retained Regulation (EU) 2015/2283. Propolis extracts standardised above conventional historical use concentrations, or presented with specific bioactive profiles not historically consumed in the UK food supply, are subject to this regime. A full Novel Food application requires safety dossiers, compositional data, and human consumption exposure assessments; the FSA's current average determination timeline is 18–24 months from validated submission, with total external consultancy and laboratory costs routinely exceeding £150,000 per product variant. This timeline effectively excludes smaller domestic producers from the innovation pathway.

A secondary barrier is MHRA enforcement under the Human Medicines Regulations 2012, which requires that any propolis product making a medicinal claim — including references to treating oral infections, healing wounds, or combating bacteria — must hold either a Marketing Authorisation or a Traditional Herbal Registration issued by the MHRA. A THR costs approximately £3,500 in fees alone and requires five years of documented traditional use evidence; full Marketing Authorisation costs are multiples higher. Local content rules do not formally apply, but the FSA's preference for EU-comparable safety standards creates a de facto barrier to third-country raw material suppliers using non-harmonised testing protocols, adding 8–12 weeks to import clearance for non-compliant certificates of analysis.

Policy-Created Opportunities in UK Propolis

The most commercially significant opportunity created by current UK policy is the FSA's Regulated Product Applications Service, launched in 2021 to streamline the Novel Food authorisation pathway specifically for post-Brexit applicants. Products achieving FSA authorisation under this service receive UK-specific marketing exclusivity protections not available under the previous EU regime, allowing first-mover applicants to establish protected category positions. Comvita and Apihealth have already invested in pre-submission engagement with the FSA's regulated products team, and the window for smaller domestic producers to file competitive dossiers before the market becomes dominated by authorised multinational products is narrowing rapidly through 2025 and 2026.

A second opportunity is created by NHS England's Community Pharmacy Contractual Framework, which expanded the scope of pharmacy-supplied health supplements eligible for reimbursement review in 2023. Propolis-based oral health and throat products meeting quality standards set by the British Pharmacopoeia's herbal monograph framework are positioned for inclusion in future expanded self-care commissioning categories. Additionally, the UK Organic Certification framework administered by the Soil Association creates a premium product tier with documented consumer willingness-to-pay uplift of approximately 40%, and Defra's Farming in Protected Landscapes programme provides grant support for beekeeping operations in designated areas, directly subsidising raw material production costs for qualifying domestic suppliers.

Market at a Glance

Leading Market Participants

• Comvita
• BeeVital
• Bee Health
• Wax Green
• Apihealth
• Manuka Health
• Nature's Answer
• Power Health
• Propolis Life
• Higher Nature

Regulatory and Policy Environment

The centrepiece of the UK propolis regulatory framework is retained Regulation (EU) 2015/2283 on Novel Foods, now administered by the Food Standards Agency under the authority of the Novel Food (England) Regulations 2018 and equivalent devolved legislation in Scotland, Wales, and Northern Ireland. The FSA's Novel Food team in York holds sole determination authority for product authorisations. Key compliance requirements include complete compositional characterisation of the propolis extract, proposed use levels and population exposure modelling, and history of use evidence. Upcoming changes include the FSA's anticipated publication of a propolis-specific technical guidance document in late 2025, which will standardise submission requirements and reduce determination variability across applicants — a development that lowers barriers for smaller UK producers relative to the current free-form dossier system.

Compared to regional peers, the UK framework is more demanding than Switzerland's, where propolis extracts are classified under the Heilmittelinstitut's simplified traditional medicines pathway, and broadly comparable to Germany's BfR-administered Novel Food process under EFSA's continuing influence. However, the UK's post-Brexit framework diverges from the EU in one commercially important respect: UK Novel Food authorisations no longer carry cross-border validity into EU member states, meaning that companies seeking to sell in both markets must maintain dual dossiers and pay dual authorisation fees — a structural cost that disproportionately burdens UK-based SMEs and is accelerating consolidation in the upstream processing segment of the market.

Long-Term Policy Outlook for UK Propolis

By 2032, the most consequential policy change anticipated for UK propolis is the FSA's planned transition to a tiered risk-proportionate Novel Food assessment framework, currently in consultation as part of the Food (Amendment) (England) Regulations review. Under this framework, propolis products with established safety records and limited bioactive concentration ranges are expected to be reclassified into a lower-burden notification pathway, substantially reducing the cost and timeline of market authorisation for standardised extracts. This regulatory relaxation will expand the number of commercially viable product SKUs, accelerate retail innovation, and reduce the concentration of authorised products in the hands of well-capitalised multinationals.

The MHRA's post-Brexit review of the Traditional Herbal Registration scheme, expected to conclude with revised guidance by 2027, is likely to introduce digital submission standards and reduce the documentary burden for well-characterised plant-derived products including propolis. Simultaneously, Defra's Land Use Framework and its implications for apiculture support funding through 2030 will determine whether domestic raw material supply can meaningfully scale. If Defra's agri-environment payment schemes incorporate dedicated beekeeping productivity metrics — under consideration within the Sustainable Farming Incentive scheme — UK-origin propolis supply could increase by 20–30%, reducing import dependency and strengthening the domestic supply chain position of UK-based manufacturers ahead of potential future trade agreement harmonisation with New Zealand and Brazil.